Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis - Wikidata - wikimedia - TriplyDB

Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis

Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis

http://www.wikidata.org/entity/Q39471624

about

Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51 Aspergillus galactosaminogalactan mediates adherence to host constituents and conceals hyphal β-glucan from the immune system.Aspergillus fumigatus CalA binds to integrin α5β1 and mediates host cell invasion A conserved C-terminal domain of the Aspergillus fumigatus developmental regulator MedA is required for nuclear localization, adhesion and virulence Posaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis.Divergent targets of Aspergillus fumigatus AcuK and AcuM transcription factors during growth in vitro versus invasive disease Recommendations for Risk Categorization and Prophylaxis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Expert Opinion (TEO-4).The Fungal Exopolysaccharide Galactosaminogalactan Mediates Virulence by Enhancing Resistance to Neutrophil Extracellular Traps.Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.Pharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration.High Intracellular Concentrations of Posaconazole Do Not Impact on Functional Capacities of Human Polymorphonuclear Neutrophils and Monocyte-Derived Macrophages In Vitro Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels.Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis.Tissue penetration of antifungal agents.Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.Intrapulmonary posaconazole penetration at the infection site in an immunosuppressed murine model of invasive pulmonary aspergillosis receiving oral prophylactic regimens.Pharmacotherapy approaches to antifungal prophylaxis.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Posaconazole-Loaded Leukocytes as a Novel Treatment Strategy Targeting Invasive Pulmonary Aspergillosis.Pharmacokinetics of posaconazole in koalas (Phascolarctos cinereus) after intravenous and oral administration.Pharmacokinetic considerations in treating invasive pediatric fungal infections.Antifungal stewardship considerations for adults and pediatrics.Uptake and efflux kinetics, and intracellular activity of voriconazole against Aspergillus fumigatus in human pulmonary epithelial cells: a new application for the prophylaxis and early treatment of invasive pulmonary aspergillosis.Serum posaconazole levels during acute myeloid leukaemia induction therapy: correlations with breakthrough invasive fungal infections.Posaconazole concentrations in human tissues after allogeneic stem cell transplantation.Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease.Understanding antifungal prophylaxis with posaconazole in hematology patients: an evolving bedside to bench story.The management of febrile neutropenia in the posaconazole era: a new challenge?Urinary tract aspergillosis in a patient with chronic kidney disease.Latest trends in fungal epidemiology inform treatment choices and stewardship initiatives.A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics/pharmacodynamics model.

P2860

Q28481694-059AE644-CEEA-4779-A46C-E62D9E097DA8 Q31129835-B6FCAE6E-2FCC-4FFC-A20E-8A7ABDD9043E Q33865358-190DE6E4-2A8F-429E-B68B-95E69B2BED59 Q34490784-F52CB147-0682-47B4-A76A-674D20A1138F Q35076830-4E729138-BADD-4E8F-B64F-442E49DF5E20 Q35098167-A0C34566-9AEB-4CDE-840C-636332606A70 Q35672258-097453AC-2BDD-44A6-AC7F-0D0C2BA7EE5A Q35817493-59F079B1-DDE4-4803-BA7B-1C1B22FC91DE Q36018743-AF3625EC-8700-4262-B3FE-233B510592F6 Q36171643-98512140-908C-4477-B2E2-540FBD4326ED Q36933346-F2B95D63-E74C-4EB4-BBAA-7B4355F0F533 Q37203849-70BA964A-7006-46B6-AB3C-A45129876E01 Q37247452-5AA8940B-7E74-4715-B217-9C49245D8F8D Q37544911-77558732-2948-4ECD-943C-DE9D9844081A Q37688257-BC537E3E-1313-4D1E-A099-83C8C510306E Q37713035-9C006863-79E3-4A73-B3EA-7CBFE24F7BD2 Q38020238-8D61D7D3-DDA3-4F8A-9F4E-79D7879EB157 Q38681635-AE782EE1-5DD4-4D11-96BA-552E79ED17E0 Q38734661-852F1907-57CD-4A21-BBCE-00AB619415D0 Q38813173-E6CD6511-1D4C-4219-8D84-B5A0D00DB186 Q38816614-009024AC-5B3F-491E-B6F3-C1C5F4A05BA6 Q38944746-71A068C4-FD36-42AE-AFE7-1F56CE9A9245 Q40396776-00F757FB-9F99-4837-B0BE-2C93DA95B51F Q41291872-6B9B2D80-8FBB-4D48-8ED6-2494152AE424 Q41886285-A808FBA1-4A05-4FB7-BD48-7A503C95C45D Q41955446-50B373FC-F1DA-4AC3-B853-A0AD06259048 Q42385111-6BB760AE-91EF-492C-83C4-BEE9673C2C0A Q43224589-98B70376-C544-420B-AFB8-B77E9C1E776E Q47127046-4D034F8F-A9D1-4E08-95A1-F189A06964B3 Q51551309-B4722563-04AE-4BF0-A440-3476B415F5D1 Q55479804-A3114EE8-2848-41AD-8FEE-01BFC7EB658F

P2860

Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis

http://www.wikidata.org/entity/Q39471624

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Concentration of antifungal ag ...... ng the efficacy of prophylaxis

@en

Concentration of antifungal ag ...... g the efficacy of prophylaxis.

@nl

type

label

Concentration of antifungal ag ...... ng the efficacy of prophylaxis

@en

Concentration of antifungal ag ...... g the efficacy of prophylaxis.

@nl

prefLabel

Concentration of antifungal ag ...... ng the efficacy of prophylaxis

@en

Concentration of antifungal ag ...... g the efficacy of prophylaxis.

@nl

P1433

Q39471624-89674B93-2283-4C66-A130-A57D5D58AF53

P1476

Q39471624-34737E29-8E10-40E8-BA26-3DDE800A823B

P2093

Q39471624-8DE447DD-2C02-454F-A239-A6514C200250

Q39471624-A73EEF64-71F8-4A60-8D49-B488E0312667

Q39471624-B1E9B602-4E63-4D36-89D3-76895B35E617

Q39471624-C32DFBA1-C079-41FF-BE90-49FFCF4C59B0

Q39471624-D5B39F62-62CB-427D-9C91-009893931986

Q39471624-D7EF0E62-65F6-4645-8C54-6BCEAF54E92E

Q39471624-D9D13FBC-3067-40CC-BE0A-4AB3F089E975

Q39471624-DF69076D-A4C9-440E-835C-3EF124E86F63

Q39471624-F596182D-7A08-422F-A98B-1E8A5C869DA7

P2860

Q39471624-06D28C63-49DA-4D9D-AC14-3B2CDC73EEAB

Q39471624-1D78F07E-CD2D-449C-8C0E-678B59FC8DCC

Q39471624-26ADFA2B-A440-4936-A67A-7FD48ADCA51C

Q39471624-26D2AF88-1BA2-41CC-A8B1-946B7A235A4E

Q39471624-314D1789-A8FE-458F-8E3F-D32FDEA5B878

Q39471624-3FBF7D21-4C67-487B-9E20-8E50F4F9356A

Q39471624-41AC9AA2-C1AE-40EF-87C0-D070847D9EE4

Q39471624-48FC072E-7587-4A8E-8C89-F604755FD703

Q39471624-4C7D811A-AE88-49A9-9A8F-3DB129204ADE

Q39471624-50DE3830-46A1-4C3C-94EC-1D5A0EB1D88E

P304

Q39471624-67B64D44-47C7-4465-833B-F28C5F837681

P31

Q39471624-BB492C3F-F30B-4994-99E3-28014D369537

P356

Q39471624-905A21E4-FD38-4AB3-AE49-E2443D309652

P407

Q39471624-B1387347-D3BA-49D8-AD62-81138C424963

P433

Q39471624-B78AEA24-FD96-44C4-9123-F2164C8E85C7

P478

Q39471624-7D316C3B-5E58-46A0-BEA9-61D1300DCF72

P577

Q39471624-025D6150-028B-4200-BA7E-41D01FB4BE43

P698

Q39471624-94265D8B-A1A6-48B4-BA1D-2A049DC125C0

P932

Q39471624-B0089A31-B372-40D7-A8D3-DB898D54662F

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Concentration of antifungal ag ...... ng the efficacy of prophylaxis

@en

P2093

A S Kristof

http://www.w3.org/2001/XMLSchema#string

D C Sheppard

http://www.w3.org/2001/XMLSchema#string

J A Fielhaber

http://www.w3.org/2001/XMLSchema#string

M Laverdiere

http://www.w3.org/2001/XMLSchema#string

N V Solis

http://www.w3.org/2001/XMLSchema#string

P Campoli

http://www.w3.org/2001/XMLSchema#string

Q Al Abdallah

http://www.w3.org/2001/XMLSchema#string

R Robitaille

http://www.w3.org/2001/XMLSchema#string

S G Filler

http://www.w3.org/2001/XMLSchema#string

P2860

Voriconazole therapeutic drug monitoring.

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

Use of bimolecular fluorescence complementation to demonstrate transcription factor interaction in nuclei of living cells from the filamentous fungus Acremonium chrysogenum.

Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.

Uptake of Aspergillus fumigatus Conidia by phagocytic and nonphagocytic cells in vitro: quantitation using strains expressing green fluorescent protein.

Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients.

Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy

Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.

P304

5732-5739

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00637-11

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21930891

http://www.w3.org/2001/XMLSchema#string

P932

3232766

http://www.w3.org/2001/XMLSchema#string